Filing Summary
Company: Bicycle Therapeutics plc
Filing: Form 8-K
Report date: October 30, 2019; filed November 5, 2019
Item: 5.02—Departure of Directors or Certain Officers; Election of Directors; Compensatory Arrangements
Business Context and Reporting Period
The filing reports a board appointment and related compensation arrangements. It does not provide operating or financial results for a reporting period.
Board Appointment and Compensation
- Veronica Jordan was elected to the Board effective October 30, 2019 as a Class I director. Her term expires at the 2020 annual general meeting.
- Dr. Jordan was appointed Chair of the Compensation Committee, replacing Richard Kender, who had served as interim chair since July 18, 2019. Mr. Kender and Janice Bourque remain committee members.
- Annual cash compensation is $40,000 for board service and $13,000 for service as Compensation Committee Chair.
- Dr. Jordan is eligible for an equity award of 23,798 ordinary shares, to be granted at a future board meeting. The award will vest in equal monthly installments over three years from the grant date, subject to continued service.
- The equity award will fully accelerate upon a sale of the Company. Reasonable out-of-pocket meeting expenses will also be reimbursed.
- Dr. Jordan entered into the Company’s standard deed of indemnity.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other operating metrics.
Material Changes, Outlook, and Risks
The principal disclosed change is the addition of Dr. Jordan to the Board and her appointment as Compensation Committee Chair. The filing states that there are no arrangements or understandings related to her election, no family relationships with Company directors or executive officers, and no material related-party interest requiring disclosure under Item 404(a) of Regulation S-K.
The future equity grant creates a potential dilution and compensation expense consideration, although the filing does not state its accounting value. Full vesting acceleration applies upon a sale of the Company.
Investor Verification Points
- Verify the date and terms of the eventual 23,798-share equity grant.
- Assess the effect of the award and other director compensation on future equity dilution and expenses.
- Review subsequent filings for changes to the Board, Compensation Committee composition, or director compensation.
- Consult the Company’s financial filings for liquidity, operating performance, debt, and forward-looking information not included in this 8-K.